Cancer treatments, organ transplants and rheumatologic diseases—dendritic cells are being used throughout medicine to create innovative treatments, according to presenters of a virtual session during the European e-Congress of Rheumatology.

Cancer treatments, organ transplants and rheumatologic diseases—dendritic cells are being used throughout medicine to create innovative treatments, according to presenters of a virtual session during the European e-Congress of Rheumatology.
For many months, the healthcare world has been significantly affected by the swift and pervasive effects of SARS-CoV-2, which causes COVID-19. The virus has severely affected the delivery of patient care by all providers, including those in hospitals and emergency care settings, who grappled with the response to massive influxes of COVID-19 patients, and those…
Jeffrey Lo, MD |
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disease of immune dysregulation characterized by unchecked inflammatory responses leading to end-organ dysfunction. Primary HLH results from inherited mutations that impair the capacity for immune regulation; secondary HLH arises from the inappropriate response to an immune stimulus, such as infection, malignancy or autoimmunity. What is less well known is…
Nobuya Abe, MD, Yuichiro Fujieda, MD, PhD, & Tatsuya Atsumi, MD, PhD |
The diagnosis of rheumatic diseases requires the exclusion of other systemic disorders. Infection, hematologic conditions, malignancies and some drugs may all lead to syndromes that closely mimic rheumatic diseases, which may lead to diagnostic delays. Idiopathic multicentric Castleman disease (iMCD) is a heterogeneous group of lymphoproliferative diseases (LPDs) characterized by systemic inflammatory manifestations.1,2 As with…
Erin Arnold, MD; William Arnold, MD; Gary Crump, MD; David Sikes, MD; Drew Johnson, MS, MBA; & Timothy Harrington, MD |
The ACR position statement on access to care proposes the goal that “… all patients have timely access to expert rheumatology care … .”1 The reality is that new and established rheumatology patient wait times are often prolonged, causing delays in necessary diagnosis and treatment. The 2005 and 2015 ACR Workforce studies document intractable and…
Ellen M. Gravallese, MD |
Looking back on last year’s ACR/ARP annual meeting, I recall the energy and excitement of attendees as they participated in sessions covering the latest scientific concepts and new directions in our field. In 2019, we piloted a number of innovative ways to modernize and enhance future ACR meetings, with the promise of delivering a transformed…
Recent research found inflammatory arthritis caused by immune checkpoint inhibitors (ICIs) may become a long-term disease, requiring rheumatology care and immunomodulatory treatment. Some patients experience active inflammatory arthritis years after ICI cessation…
With usual in-person fundraisers and meetings not possible during the pandemic, RheumPAC is finding creative ways to keep advocating for influential legislation and ensure rheumatology’s voice is heard in Washington, D.C.
Carolyn Crist |
(Reuters Health)—During the COVID-19 pandemic, an inflammatory condition similar to Kawasaki disease has been reported in children and adolescents, and now two groups of New York doctors each describe a case, one in a 36-year-old woman and one in a 45-year-old man.1 “We’re still learning how COVID-19 is affecting children and adults. The better we…
Rheumatologists who are outstanding clinicians, provide consistently exceptional care to patients and serve as role models for colleagues and trainees are in the spotlight in our Lessons from a Master Clinician series. Here, we offer insights from clinicians who have achieved a level of distinction in the field of rheumatology and who are respected by…